Current Therapies for Cholestatic Diseases

Méndez-Sánchez, Nahúm; Coronel-Castillo, Carlos E.; Ordoñez-Vázquez, Ana Luisa

doi:10.3390/biomedicines11061713

Cited by 5 publications

(1 citation statement)

References 105 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) are the main types of chronic cholestatic liver disease. 4 In recent years, significant advancements have been made in understanding the pathogenesis and management of cholestatic liver disease, leading to a continuous increase in potential therapeutic targets and ongoing clinical trials. This review provides a comprehensive summary of the latest developments in the management of cholestatic liver disease.…”

Section: Introductionmentioning

confidence: 99%

Progress in the Management of Patients with Cholestatic Liver Disease: Where Are We and Where Are We Going?

Luo,

2024

J Clin Transl Hepatol

View full text Add to dashboard Cite

Cholestatic liver disease is a group of diseases in which bile acid accumulates in the liver for various reasons, resulting in abnormal liver biochemical indicators and histological damage. Cholestasis can be divided into intrahepatic cholestasis and extrahepatic cholestasis, which will contribute to liver damage and progress to liver fibrosis and cirrhosis. Primary biliary cholangitis (PBC) and primary sclerosing cholangitis are the two most typical cholestatic liver diseases. Ursodeoxycholic acid is currently the first-line treatment for PBC, while obeticholic acid, budesonide and fibrates have also shown good potential in the treatment of PBC. There are currently no official drugs approved to treat primary sclerosing cholangitis, and the use of ursodeoxycholic acid may have certain clinical benefits. At present,

show abstract

Section: Introductionmentioning

confidence: 99%

Progress in the Management of Patients with Cholestatic Liver Disease: Where Are We and Where Are We Going?

Luo,

2024

J Clin Transl Hepatol

View full text Add to dashboard Cite

show abstract

Gardenia jasminoides Ellis. Polysaccharides Alleviated Cholestatic Liver Injury by Increasing the Production of Butyric Acid and FXR Activation

Wang,

Tian,

Zhu

et al. 2024

Phytotherapy Research

View full text Add to dashboard Cite

Gardenia jasminoides Ellis. polysaccharide (GPS) can protect against cholestatic liver injury (CLI) by regulating nuclear farnesoid X receptor (FXR).However, the mechanism via which GPS mediates the FXR pathway remains unclear. The aim of this study was to investigate the mechanism. Firstly, an alpha‐naphthylisothiocyanate‐induced cholestatic mouse model was administered with GPS to evaluate its hepatoprotective effects. The metabolic pathways influenced by GPS in cholestatic mice were detected by serum metabolomics. The effect of GPS on bile acid (BA) homeostasis, FXR expression, and liver inflammation were investigated. Second, the intestinal bacteria metabolites affected by GPS in vivo and in vitro were determined. The activation of FXR by sodium butyrate (NaB) was measured. Finally, the effects of NaB on cholestatic mice were demonstrated. The main pathways influenced by GPS involved BA biosynthesis. GPS upregulated hepatic FXR expression, improved BA homeostasis, reduced F4/80+ and Ly6G+ positive areas in the liver, and inhibited liver inflammation in cholestatic mice. Butyric acid was the most notable intestinal bacterial metabolite following GPS intervention. NaB activated the transcriptional activity of FXR in vitro, upregulated hepatic FXR and its downstream efflux transporter expression, and ameliorated disordered BA homeostasis in CLI mice. NaB inhibited the toll‐like receptor 4/nuclear factor (TLR4/NF‐κB) pathway and reduced inflammation and CLI in mice. An FXR antagonist suppressed the effects. In conclusion, GPS increased butyric acid production, which can activate hepatic FXR, reverse BA homeostasis disorder, and inhibit the TLR4/NF‐κB inflammatory pathway, exerting protective effects against CLI.

show abstract

Gut Microbiome and Bile Acid Interactions: Mechanistic Implications for Cholangiocarcinoma Development, Immune Resistance, and Therapy

Wu,

Bayatpour,

Hylemon

et al. 2024

The American Journal of Pathology

View full text Add to dashboard Cite

Current Therapies for Cholestatic Diseases

Cited by 5 publications

References 105 publications

Progress in the Management of Patients with Cholestatic Liver Disease: Where Are We and Where Are We Going?

Progress in the Management of Patients with Cholestatic Liver Disease: Where Are We and Where Are We Going?

Gardenia jasminoides Ellis. Polysaccharides Alleviated Cholestatic Liver Injury by Increasing the Production of Butyric Acid and FXR Activation

Gut Microbiome and Bile Acid Interactions: Mechanistic Implications for Cholangiocarcinoma Development, Immune Resistance, and Therapy

Contact Info

Product

Resources

About